Skip to content
Companies

Alloy Therapeutics

Transgenic mice for human antibody discovery

Raised to date

$30M

of $40M offered across 1 Form D filing

Still open
$10M
Investors
11
Last filed
Apr 15, 2026

About

Alloy Therapeutics is a biotechnology company that licenses foundational drug-discovery platforms and runs discovery programs for pharmaceutical and biotech partners. Its flagship ATX-Gx platform is a set of transgenic mice engineered to express human antibody genes for fully human antibody discovery, licensed by more than 170 partners since its 2019 launch. Alloy has expanded beyond antibodies into T-cell receptor mimics, genetic medicines, and cell therapies, with AI/ML capabilities added through its 2021 DeepCDR acquisition. The company operates from Waltham, MA with additional sites in Athens GA, Cambridge UK, Basel, and Fujisawa, Japan.

Sells access to pre-competitive discovery technology on deliberately partner-friendly terms — a January 2025 ATX-Gx licensing model with no annual access fee or development milestones — and reinvests 100% of profits into new platform development, positioning itself as an ecosystem enabler rather than a competitor to its partners' pipelines.

Funding

  • EquityFiled Apr 15, 2026Form D
    $30M/ $40M

Product

ATX-Gx

Antibody discovery platform

A licensable platform of transgenic mouse strains engineered to express human antibody genes, producing robust immune responses with human-like immune repertoires for fully human therapeutic antibody discovery.

  • Multiple transgenic mouse strains expressing human antibody genes
  • Human-like immune repertoires with wild-type-strength immune responses
  • Licensing model without annual access fees or development milestones

Built for

Pharmaceutical and biotech companies and academic research institutions running biologics discovery programs

People on file